NANBIOSIS Presented at ESB 2026 in Antwerp

NANBIOSIS was presented at ESB 2026 in Antwerp, highlighting its role in connecting academia and industry in biomedical research.

Antwerp, September 2026 — NANBIOSIS participated in the 35th Annual Conference of the European Society for Biomaterials (ESB 2026), held from 7 to 11 September 2026 in Antwerp, Belgium, marking the 50th anniversary of the European Society for Biomaterials.

Representing NANBIOSIS, Gabriel Alfranca, Internationalization and Communication Manager, presented a poster introducing the infrastructure and its role in supporting biomedical research and development. The poster, listed as D2-P031, was titled “NANBIOSIS: A distributed research infrastructure bridging Academia and Industry up to preclinical development.”

The conference brought together scientists, clinicians, engineers, industry representatives and students working across the biomaterials field. Its scientific programme covered areas including tissue engineering, regenerative medicine, biofabrication, drug delivery, medical devices, biomaterials, advanced manufacturing and clinical translation.

ESB 2026 provided an opportunity for NANBIOSIS to increase its visibility within the international biomaterials and biomedical research community and to introduce its capabilities to researchers and professionals interested in translating innovative technologies towards preclinical development.

Through its participation in international scientific events such as ESB 2026, NANBIOSIS continues to promote collaboration and awareness of its distributed research infrastructure among academic and industrial communities.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

If you want to collaborate with us, visit our Order Request page.

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them: